Research programme: botulinum toxin therapeutics - DOR BioPharma
Latest Information Update: 28 Aug 2007
At a glance
- Originator DOR BioPharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Botulism
Most Recent Events
- 21 Feb 2005 Preclinical trials in Botulism in USA (unspecified route)